Abstract
(Abstracted from Gynecol Oncol 2024;181:170–178 Identification of germline and somatic pathogenic variants as well as homologous recombination deficiency (HRD) can contribute to the prediction of treatment response, prognostic outcome, and suitability for targeted agents. Germline genetic testing can also serve to inform risk for other malignancies and prompt risk management for at-risk relatives.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call